



**ASAM** The Voice of Addiction Medicine  
American Society of Addiction Medicine

## Medicaid Coverage of Medications for the Treatment of Opioid Use Disorder

In Kansas between 2008-2012, persons enrolled in substance use treatment programs that prescribed methadone **increased 114%**. In 2012 in Kansas, **12.7%** of persons aged 12 and older who met criteria for having a drug use disorder received treatment<sup>α</sup>.

**KANSAS**

### State Benefits at a Glance<sup>β</sup>...

#### Methadone

Kansas Medicaid does not cover methadone under Fee-For-Service (FFS) plans.

**Buprenorphine/Naloxone film (Suboxone<sup>®</sup>), Buprenorphine/Naloxone tablets (generic), Buprenorphine/Naloxone tablets (Zubsolv<sup>®c</sup>) and Buprenorphine tablets (generic).**

#### Medication Limitations

Kansas Medicaid covers Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets under FFS and Managed Care (MC) plans with the following limitations:

- In order to approve Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets for the treatment of opioid use disorder, patients must be enrolled in, or have documented proof of, SUD\* counseling.
- Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets require prior authorization for use.
- Zubsolv appears on Kansas Medicaid's Preferred Drug List.
- In most cases, Zubsolv is subject to the same prior authorization requirements as the surveyed buprenorphine products.

Kansas covers Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets as a pharmacy benefit under FFS plans.

Suboxone, buprenorphine/naloxone tablets, and buprenorphine tablets are not listed on Kansas' preferred drug list for FFS plans. No information was provided regarding coverage for use in organized specialty outpatient treatment programs (OTPs), accredited outpatient narcotic treatment programs (NTPs), or physician's offices.

<sup>α</sup> Data from SAMHSA's State and Metro Reports accessed [http://www.samhsa.gov/data/States\\_In\\_Brief\\_Reports.aspx](http://www.samhsa.gov/data/States_In_Brief_Reports.aspx)

<sup>β</sup> Data as of spring 2014.

<sup>c</sup> Zubsolv was not included in the original survey, as the medication was not FDA approved until fall of 2013. This summary reflects only information related to Preferred Drug List (PDL) and formulary inclusion obtained from pharmacy and State websites.

\*In Kansas, substance Use Disorder (SUD) counseling is a covered Medicaid benefit under FFS plans.



# ASAM

The Voice of Addiction Medicine

American Society of Addiction Medicine

## State Benefits at a Glance (continued)...


### Injectable Naltrexone (VIVITROL®)

When the survey was conducted in 2013, there was no information provided on the use of Vivitrol, other than the fact that this medication is not included on the preferred drug list in Kansas.

**As of June 2013, Kansas had a maximum of three substance abuse treatment admissions per lifetime, per patient.**

## Medicaid Benefits for Treatment of Opioid Dependence Nationwide

Number of Medications Covered under Fee-For-Service Medicaid Plans By State



Data collected by the Avisa Group and Treatment Research Institute 2013-2014